Cure Duchenne Ventures LLC Provides $1 Million to MyoTherix to Advance Promising Research to Treat Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–CureDuchenne Ventures LLC, a company that funds research to find a cure
for Duchenne muscular dystrophy, announced today that they have invested
$1 million in MyoTherix Inc., a biotechnology company focused on
developing novel therapeutics for the treatment of Duchenne and other
muscular dystrophies. The funds will support the Company’s preclinical
studies in mouse models of Duchenne muscular dystrophy as well as
preclinical development studies.

“We are delighted to partner with MyoTherix on this important research
that addresses a new mechanism targeting both cardiac and skeletal
muscle weakness in Duchenne,” said Debra Miller, president of
CureDuchenne Ventures. “This research has the potential to provide new
treatment options for all boys with Duchenne, regardless of their
mutation.”

Duchenne is an inherited fatal disease that causes muscles to
degenerate. It impacts approximately 1 in 3,500 boys. Boys with Duchenne
are usually diagnosed by age 5, in a wheelchair by 12 and most don’t
survive their mid-20s. Heart failure is the leading cause of death in
patients with Duchenne. There is currently no approved treatment or cure
for Duchenne.

“MyoTherix’s lead research program intends to improve both cardiac and
skeletal muscle function, as well as reduce inflammation and facilitate
new muscle regeneration,” said John Kincaid, co-Founder of MyoTherix
Inc. “We are pleased to work with the team at CureDuchenne and look
forward to developing this new approach to the treatment of this
devastating disease.”

“CureDuchenne Ventures continues to invest in a cure for Duchenne by
funding the most promising research that focuses on protein replacement,
gene correction, cardiac and anti-inflammatory and anti-fibrosis,” said
Miller. “MyoTherix is a potential treatment that could help all those
with Duchenne.”

CureDuchenne Ventures LLC was formed by CureDuchenne, a national
nonprofit that has funded seven research projects that have advanced to
human clinical trials. CureDuchenne has leveraged $100 million in pharma
and biotech research and development investments. Now three of the
projects CureDuchenne supported with funding, BioMarin Pharmaceutical,
Sarepta Therapeutics and PTC Therapeutics, are the closest to becoming
the first drugs to be approved for the treatment of the disorder.

About CureDuchenne Ventures

CureDuchenne Ventures LLC collaborates with pharmaceutical and
biotechnology companies to facilitate the development of drugs to treat
Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by
CureDuchenne, a national nonprofit that has a successful track record of
supporting research and raising awareness of the disease.

About CureDuchenne

CureDuchenne was founded in 2003 with a focus on saving the lives of
those with Duchenne muscular dystrophy, a disease that affects more than
300,000 boys worldwide. With support from CureDuchenne the FDA could
approve three pharmaceutical treatments within the next year. These
treatments may lessen the effects of the disease for those with certain
mutations of Duchenne, but there is still much to be done to find a
cure. For more information, please visit CureDuchenne.org
and follow us on Facebook,
Twitter
and YouTube.

About MyoTherix Inc.

MyoTherix Inc. is a venture-supported biotechnology company focused on
developing novel therapeutics for the treatment of muscle disorders. Its
lead product opportunity utilizes an innovative and novel approach to
target both cardiac and skeletal muscle weakness.

Contacts

CureDuchenne
Karen Harley, 949-872-2552

?>